Instrument Inactif

Communiqués NEOPROBE OTC Bulletin Board

Actions

NEOP

US6405181065

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

07/11	Retrait d'une requête visant à limiter les pouvoirs du débiteur en possession dans la faillite de Navidea Biopharmaceuticals, Inc.	CI
03/11	Navidea Biopharmaceuticals : une motion demande la limitation des pouvoirs du débiteur en possession ou le rejet de la procédure de faillite	CI

Communiqués

09/10/25	Navidea Biopharmaceuticals Inc. Files for Bankruptcy	AQ
04/12/23	Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	AQ
15/11/23	Navidea: Q3 Earnings Snapshot	AQ
06/10/23	Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	BU
10/08/23	Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	BU
31/07/23	Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	AQ
31/07/23	Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities	BU
29/07/23	Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	BU
27/07/23	Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	BU
13/07/23	Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down	BU
03/07/23	Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	AQ
30/06/23	Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	BU
16/06/23	NAVIDEA BIOPHARMACEUTICALS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
16/06/23	Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock	BU
16/06/23	Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment	BU
07/06/23	Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update	BU
05/06/23	Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	AQ
05/06/23	NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
02/06/23	Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	BU
01/06/23	Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down	BU
23/05/23	Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market	BU
11/05/23	Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer	BU
08/05/23	Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications	BU
28/04/23	NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/04/23	Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million, Secures New $2.75 Million Equity Line of Credit	AQ